Effectiveness of electronic patient reporting outcomes, by a digital telemonitoring platform, for prostate cancer care: the Protecty study
Open accessAbstract
Research aim and purpose: The benefits of Electronic Patient -Reported Outcomes (e-PRO) for telemonitoring are well established, allowing early detection of illnesses and continuous monitoring of patients. The primary objective of the PROTECTY study was to assess the compliance with patient use of the telemonitoring platform Cureety. An exploratory objective was to assess if the first-month health status is a prognostic factor of progression free-survival (PFS) and overall survival (OS) for prostate cancer patient. Methods: This prospective study was conducted at the Military Hospital Bégin on prostate cancer patients. Patients were allowed to respond to a symptomatology questionnaire based on CTCAE v.5.0, personalized to their pathology and treatment. An algorithm evaluates the health status of the patient based on the reported adverse events, with a classification into 2 different states: Good Health Status (GHS) and Poor Health status (PHS). Results: Sixty-one patients were enrolled between July 1st, 2020 and September 30th, 2021. The median age was 74.0 (range 58.0–94.0). 78% presented a metastatic stage, and the most represented cancer was mHSPC. Overall, 2,457 questionnaires were completed by the patients, 4.0% resulted in a health classification in to monitor or critical state. 87% of patients were classified in the GHS group. The compliance was 72% in the overall population during the first month, 71% in GHS group and 75% in PHS group. The median follow-up was 8 months. PFS at 6 months was 84% in GHS group vs. 57% in PHS group, p = 0.19. OS at 6 months was 98% in GHS group vs. 83% in PHS group, p = 0.31. Conclusions: Our study showed that compliance was satisfactory. The feasibility of remote monitoring for prostate cancer patients means that they should benefit from its implementation. Our study is also the first to assess the correlation between treatment tolerance and survival. The initial results suggest that e-PRO assessment could help identify in the early stages the patients that require further health assessment and potential therapeutic changes. While further follow-up of more patients will be required, our study highlights the importance of e-PRO in cancer patient care.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Smaller, single-institution studies of RPM in routine care in France reported an overall 66%-72% adherence rate with weekly ePRO reporting.
“In addition, smaller, single-institution studies of RPM in routine care in France reported an overall 66%–72% adherence rate with weekly ePRO reporting.30,31”
From Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium (2024) · cites this paper as [31]
The Results (Compliance; page unavailable) report 72% adherence in the first month among 61 patients at one institution. But adherence was 59% over the full monitoring period, and questionnaires were due weekly or biweekly depending on treatment. This paper therefore does not support describing 72% as an overall adherence rate with weekly reporting. (LLM, conf=0.91)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864 · see citing works
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856 · see citing works
Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017) · JAMA · doi:10.1001/jama.2017.7156 · Cited by 2,302 · see citing works
Armstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J. M., Villers, A. A., Azad, A., Alcaraz, A., Alekseev, B. Y., Iguchi, T., Shore, N. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00799 · Cited by 1,219 · see citing works
Dueck, A. C., Mendoza, T. R., Mitchell, S. A., Reeve, B. B., Castro, K. M., Rogak, L. J., Atkinson, T. M., Bennett, A. V., Denicoff, A. M., O'Mara, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2639 · Cited by 1,030 · see citing works
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Smith, M. R., Hussain, M., Fred Saad, C., Fizazi, K. S., Sternberg, C. N., Crawford, E. D., Kopyltsov, E., Park, C. H., Alekseev, B. Y., Montesa-Pino, Á., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119115 · Cited by 1,024 · see citing works
Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A., Tombal, B., Supiot, S., Berthold, D., Ronchin, P., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00367-1 · Cited by 847 · see citing works
Fizazi, K. S., Tran, N., Fein, L. E., Matsubara, N., Rodríguez-Antolín, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30082-8 · Cited by 842 · see citing works
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792 · see citing works
Remote patient monitoring: a comprehensive study
Malasinghe, L. P., Ramzan, N., & Dahal, K. (2019) · Journal of Ambient Intelligence and Humanized Computing · doi:10.1007/s12652-017-0598-x · Cited by 534 · see citing works
Denis, F., Lethrosne, C., Pourel, N., Molinier, O., Pointreau, Y., Domont, J., Bourgeois, H., Senellart, H., Trémolières, P., Lizée, T., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx029 · Cited by 482 · see citing works
Attard, G., Murphy, L. R., Clarke, N. W., Cross, W., Jones, R. J., Parker, C. C., Gillessen, S., Cook, A. D., Brawley, C., Amos, C. L., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02437-5 · Cited by 390 · see citing works
Kluetz, P. G., Chingos, D. T., Basch, E., & Mitchell, S. A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159514 · Cited by 363 · see citing works
Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives
Aapro, M., Bossi, P., Dasari, A. N., Fallowfield, L. J., Gascón, P., Geller, M. A., Jordan, K., Kim, J. W., Martin, K., & Porzig, S. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05539-1 · Cited by 318 · see citing works
Attard, G., Murphy, L. R., Clarke, N. W., Cross, W. R., Jones, R. J., Parker, C. C., Gillessen, S., Cook, A. D., Brawley, C., Amos, C. L., et al. (2022) · BORIS (University Library Bern) · doi:10.48350/164184 · Cited by 303 · see citing works
Agreement between patient-reported symptoms and their documentation in the medical record.
Pakhomov, S., Jacobsen, S. J., Chute, C. G., & Roger, V. L. (2008) · PubMed · Cited by 273 · see citing works
VA Telemedicine: An Analysis of Cost and Time Savings
Russo, J. E., McCool, R. R., & Davies, L. (2015) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2015.0055 · Cited by 209 · see citing works
Movsas, B., Moughan, J., Sarna, L., Langer, C. J., Werner‐Wasik, M., Nicolaou, N., Komaki, R. R., Machtay, M. X., Wasserman, T. H., & Bruner, D. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7420 · Cited by 186 · see citing works
Using e-technologies in clinical trials
Rosa, C., Campbell, A. N. C., Miele, G. M., Brunner, M., & Winstanley, E. L. (2015) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.07.007 · Cited by 147 · see citing works
The assessment of telemedicine to support outpatient palliative care in advanced cancer
Hennemann-Krause, L., Lopes, A. J., Araújo, J. A., Petersen, E. M., & Nunes, R. A. (2015) · Palliative and Supportive Care · doi:10.1017/s147895151400100x · Cited by 79 · see citing works
Tran, C. N., Dicker, A. P., Leiby, B. E., Gressen, E. L., Williams, N. L., & Jim, H. (2019) · Journal of Medical Internet Research · doi:10.2196/12689 · Cited by 66 · see citing works
Prognostic Significance of Patient-Reported Outcomes in Cancer
Kerrigan, K. C., Patel, S. B., Haaland, B. A., Ose, D. J., Chalmers, A. W., Haydell, T., Meropol, N. J., & Akerley, W. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00329 · Cited by 61 · see citing works
Kim, Y., Park, J.-E., Lee, B., Jung, C. H., & Park, D. A. (2018) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x18782599 · Cited by 35 · see citing works
Patient-reported outcomes in metastatic castration-resistant prostate cancer
Fallowfield, L. J., Payne, H. A., & Jenkins, V. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.100 · Cited by 32 · see citing works
Distant mood monitoring for depressive and bipolar disorders: a systematic review
van der Watt, A. S. J., Odendaal, W., Louw, K.-A., & Seedat, S. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02782-y · Cited by 27 · see citing works
The Use of Telemedicine in Cancer Clinical Trials: Connect-Patient-to-Doctor Prospective Study
Meghiref, Y., Parnot, C., Duverger, C., Difoum, F. L., Gourden, A., Yssaad, H., Leiterer, C., Bedekovic, C., Blanchard, J., Ammar, H. N., et al. (2021) · JMIR Cancer · doi:10.2196/31255 · Cited by 18 · see citing works
Self-citationPatient-reported Outcomes in Metastatic Castration-sensitive Prostate Cancer in the Adjuvant Setting
Morgans, A. K., & Stockler, M. R. (2019) · European Urology Focus · doi:10.1016/j.euf.2018.12.007 · Cited by 15 · see citing works
Rivière, C., Brureau, L., Parnot, C., Becherirat, S., Duverger, C., Picchi, H., Le Roy, A., Vuagnat, P., Schernberg, A., Vanquaethem, H., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34196 · Cited by 12 · see citing works
Self-citation1703P Effectiveness of a digital telemonitoring platform for elderly cancer patient (EP) care
Hélissey, C., Duverger, C., Vanquaethem, H., Meghrief, Y., & Parnot, C. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1675 · Cited by 2 · see citing works
Self-citationCella, D. F., Hamilton, M., Blum, S. I., Ivanescu, C., Williams, A., Ejzykowicz, F., & Motzer, R. J. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.4502 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Franzoi, M. A., Ferreira, A. R., Lemaire, A., Rodriguez, J., Grosjean, J., Ribeiro, J. M., Polastro, L., Grellety, T., Artignan, X., Le Du, K., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101005 · Cited by 50 · see citing works
“30,31 In our study, the overall adherence to weekly ePRO reporting was 82% including elderly patients who represented 45% of the cohort.”
BackgroundSalmani, H., Nasiri, S., Alemrajabi, M., & Ahmadi, M. (2024) · Frontiers in Rehabilitation Sciences · doi:10.3389/fresc.2024.1427712 · Cited by 18 · see citing works
Salmani, H., Nasiri, S., & Ahmadi, M. (2024) · Digital Health · doi:10.1177/20552076241257146 · Cited by 19 · see citing works
Electronic patient-reported outcome systems and capabilities in cancer care: a systematic review
Salmani, H., Nasiri, S., Alemrajabi, M., & Ahmadi, M. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1560533 · Cited by 4 · see citing works
How to monitor the side effects of treatments in cancer patients
Palma, M. D. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001123 · Cited by 2 · see citing works
Prostate Cancer Surgical Innovations: Evolution from Open to Minimally Invasive Techniques
Gaudji, G. R., Mabonga, L., Damane, B. P., Morolo, V., Batra, J., Maimela, C., & Dlamini, Z. (2024) · Springer eBooks · doi:10.1007/978-3-031-64388-0_8 · Cited by 1 · see citing works
Cassuto, O., Schmitt, A., Hélissey, C., Gobert, A., Mathiéu, R., Bouteleux, C., Mourey, L., Jovenin, N., & Joly, F. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.04.009 · Cited by 1 · see citing works
- Authors
- Helissey, C., Parnot, C., Rivière, C., Duverger, C., Schernberg, A., Becherirat, S., Picchi, H., Le Roy, A., Vuagnat, P., Pristavu, R., Vanquaethem, H., & Brureau, L.
- Affiliations
- Hôpital d'Instruction des Armées Bégin (FR)
- Inserm (FR)
- Venue
- Frontiers in Digital Health
- Publisher
- Frontiers Media SA
- Published
- 2023-05-08
- Volume
- 5
- Pages
- 1104700-1104700
- ISSN
- 2673-253X (ISSN-L)
- PMC
- PMC10203955
- OpenAlex
- W4378348120
- Cited by
- 7
- References
- 30
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Digital Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Telemedicine and Telehealth Implementation
- Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- prostate cancer, electronic patient-reported outcomes, remote patient monitoring, treatment tolerance, health status classification, progression-free survival, overall survival, metastatic hormone-sensitive prostate cancer, medication adherence, adverse event reporting, CTCAE
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
